In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Dead languages aren't as unimportant as they seem, because learning Latin, Sanskrit and Ancient Greek will make coding easier ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

A marriage of formal methods and LLMs seeks to harness the strengths of both.